A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

NCT06847542 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DEVICE: Susvimo PDS Implant
DRUG: Ranibizumab

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]